Diligence memo · auto-generated · as of July 2, 2026
Galera Therapeutics, Inc.
Galera Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Galera Therapeutics, Inc. operates in Pharmaceuticals, based in MALVERN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Galera Therapeutics, Inc. has raised $144M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $70M on 2018-08-30.
Most recent recorded round closed around 2024-12-30.
Valuation (modeled)modeled
Provath models Galera Therapeutics, Inc. at approximately $21M (range $9.4M–$30M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.04× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 18 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 95% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 28% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.